Skip to content

Analysis of immune correlation factors affecting AMH in female Rheumatic patients of childbearing Age

Analysis of immune correlation factors affecting AMH in female Rheumatic patients of childbearing Age

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047643
Enrollment
Unknown
Registered
2021-06-21
Start date
2021-06-20
Completion date
Unknown
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune abortion

Interventions

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 48 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria of the experimental group: 1. In line with the diagnostic criteria of systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, ankylosing spondylitis, and other four immunological diseases; 2. Women of childbearing age (20-50 years old); 3. All patients were newly diagnosed with rheumatism and had not been treated with glucocorticoids, immunosuppressants, biological agents or other anti-tumor drugs in the past. Inclusion criteria for control group: 1. Women of normal childbearing age (20-50 years old); 2. No metabolic diseases and definite autoimmune diseases; 3. No pelvic space occupying lesions or other malignant tumors.

Exclusion criteria

Exclusion criteria: Exclusion criteria of the experimental group: 1. Patients with pelvic space-occupying lesions, polycystic ovary syndrome, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, and other diseases; 2. Patients who have received ovarian surgery and pelvic radiation therapy; 3. Patients who have been pregnant or given birth within the past 3 months. Exclusion criteria for control group: 1. Patients with pelvic space occupying lesions, polycystic ovary syndrome, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome and other diseases; 2. Patients who have received ovarian surgery and pelvic radiation therapy; 3. Patients who have been pregnant or given birth within the past 3 months; 4. Those who have definite autoimmune disease or are positive for autoantibodies.

Design outcomes

Primary

MeasureTime frame
Anti-Müllerian hormone level;

Countries

China

Contacts

Public ContactWang Meiying

Shenzhen Second People's Hospital

wmy99wmy99@163.com+86 13723769919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026